PMID- 24040459 OWN - NLM STAT- MEDLINE DCOM- 20140418 LR - 20211021 IS - 1936-2625 (Electronic) IS - 1936-2625 (Linking) VI - 6 IP - 9 DP - 2013 TI - Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature. PG - 1919-28 AB - An 85-year-old man presented with pain and numbness in the left buttock, and physical examination revealed an approximately 7 cm mass extending from the first to the third sacral vertebrae; biopsy of the mass led to the diagnosis of CD10-negative, BCL6-weakly positive, MUM1-positive, non-germinal center (non-GC) type diffuse large B-cell lymphoma (DLBCL). Furthermore, serological testing showed negative results for Epstein-Barr virus (EBV) infection, and fluorescence in situ hybridization (FISH) revealed a MYC translocation. Radiographs showed no remarkable osteolytic bone destruction, and the patient was staged with Stage IAE. After 8 cycles of rituximab therapy and 6 cycles of CHOP therapy, complete remission has been maintained until now, approximately 1 year after the treatment. Primary sacral lymphoma is very rare, with only 6 reported cases, including the present one. A review of the reported cases revealed that the disease predominantly affects elderly men, is usually non-GC-type DLBCL and stage IAE, measures approximately 2-7 cm in diameter in general, and does not show early recurrence after chemotherapy or chemoradiotherapy. There is no report in the literature yet of primary sacral DLBCL with MYC translocation, and this is the first case report. On the other hand, 35 cases of CD10-negative DLBCL with MYC translocation, including the present one, have been reported, and a review of the reported cases showed that the disease predominantly affects Asians, middle-aged or elderly men, shows positivity for either BCL6 or MUM1 and negativity for EBV, and has a high international prognostic index and poor prognosis. FAU - Shimada, Asami AU - Shimada A AD - Department of Hematology, Juntendo University Urayasu Hospital Urayasu, Japan. FAU - Sugimoto, Kei-Ji AU - Sugimoto KJ FAU - Wakabayashi, Mutsumi AU - Wakabayashi M FAU - Imai, Hidenori AU - Imai H FAU - Sekiguchi, Yasunobu AU - Sekiguchi Y FAU - Nakamura, Noriko AU - Nakamura N FAU - Sawada, Tomohiro AU - Sawada T FAU - Ota, Yasunori AU - Ota Y FAU - Komatsu, Norio AU - Komatsu N FAU - Noguchi, Masaaki AU - Noguchi M LA - eng PT - Case Reports PT - Journal Article PT - Review DEP - 20130815 PL - United States TA - Int J Clin Exp Pathol JT - International journal of clinical and experimental pathology JID - 101480565 RN - 0 (Biomarkers, Tumor) RN - 0 (MYC protein, human) RN - 0 (Proto-Oncogene Proteins c-myc) SB - IM MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Biomarkers, Tumor/analysis/*genetics MH - Biopsy MH - Genetic Predisposition to Disease MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Lymphoma, Large B-Cell, Diffuse/chemistry/drug therapy/*genetics/pathology MH - Magnetic Resonance Imaging MH - Male MH - Phenotype MH - Positron-Emission Tomography MH - Proto-Oncogene Proteins c-myc/*genetics MH - Remission Induction MH - *Sacrum/pathology MH - Spinal Neoplasms/chemistry/drug therapy/*genetics/pathology MH - Tomography, X-Ray Computed MH - *Translocation, Genetic MH - Treatment Outcome PMC - PMC3759501 OTO - NOTNLM OT - CD10-negative OT - MYC OT - Primary sacral lymphoma OT - non-germinal center DLBCL OT - paraffin-embedded tissue section-fluorescence in-situ hybridization EDAT- 2013/09/17 06:00 MHDA- 2014/04/20 06:00 PMCR- 2013/08/15 CRDT- 2013/09/17 06:00 PHST- 2013/07/16 00:00 [received] PHST- 2013/07/30 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2014/04/20 06:00 [medline] PHST- 2013/08/15 00:00 [pmc-release] PST - epublish SO - Int J Clin Exp Pathol. 2013 Aug 15;6(9):1919-28. eCollection 2013.